Prior Authorization Reform: Underwrite a Smaller, More Complex Workload

CMS’s interoperability requirements give buyers a defined implementation problem. They also create a risk of combining mandatory compliance expenditure with discretionary productivity claims. I would separate the minimum compliant configuration from the additional workflow investment and evaluate each on its own terms.

A working interface can still leave staff correcting incomplete clinical context or reconciling conflicting status records. Acceptance testing should therefore include unsuccessful submissions, policy changes, missing information and handoffs back to the provider. The costly cases determine the residual staffing requirement.

The economic comparison is total cost per resolved request, accompanied by time to the relevant care decision. A lower unit processing cost is insufficient if resubmissions, appeal work or patient abandonment rise elsewhere in the pathway.

A payer’s decision to remove selected authorization requirements changes the addressable workload. It does not automatically reduce the complexity of the requests that remain. The residual pool may require more clinical context and more judgment, limiting the proportion of costs that can be removed.

I would stress-test a vendor contract under declining request volumes and a more difficult case mix. A minimum-volume commitment can transfer the financial benefit of simplification away from the buyer. A purely outcome-based fee can create other distortions if approval rates are rewarded without regard to appropriateness.

A more durable arrangement separates platform availability, implementation work and service-level performance. It should pay for reliable administration while keeping coverage decisions with the authorized parties. The contract must make simplification economically acceptable to both buyer and supplier.

FDA’s internal data and AI modernization provides an example of deploying tools within an accountable institution. It does not demonstrate that a commercial product improves a regulated workflow or predicts how quickly regulatory scrutiny will change.

The useful design question is how an organization retains responsibility when AI assembles information or recommends action. I would require source provenance, recorded changes and an identifiable reviewer where the decision carries clinical, coverage or regulatory consequences.

These controls consume resources and should appear in the operating budget. The procurement case strengthens when review is concentrated on defined exceptions and the organization can explain which risks that review addresses, rather than placing nominal human approval on every automated step.

A structured authorization history can distinguish several problems that look identical in a denial dashboard: an ineligible request, missing evidence, a policy disagreement, a status failure or a service that never occurs. Each requires a different intervention and has a different owner.

I would reconcile authorization outcomes with scheduling, completed care and eventual payment. Faster approval has little revenue value when the visit does not take place; fewer denials have little cash value when underpayment or collection delays persist. This reconciliation keeps process metrics connected to the business.

The resulting management review should allocate resources by failure cause and controllability. It should also retain requests that could not be completed, so apparent improvement cannot be produced by excluding complex patients or difficult payer relationships.

Documentation, coding and authorization tools increasingly address adjacent parts of the same transaction. Their integration can reduce duplicate work, but broader scope also increases dependency on one supplier and the cost of correcting a shared error.

I would evaluate the combined record through a disputed claim: which source supports the coding, which policy applied, who approved a material change and whether the provider can export the evidence. This test is more informative than a successful demonstration on an uncomplicated encounter.

The purchase decision should compare integration benefits with concentration risk, migration cost and the availability of manual recovery. A platform earns a larger role when it improves both routine throughput and the institution’s ability to resolve exceptions.